[go: up one dir, main page]

MA32120B1 - Nouveaux composes chimiques - Google Patents

Nouveaux composes chimiques

Info

Publication number
MA32120B1
MA32120B1 MA32465A MA32465A MA32120B1 MA 32120 B1 MA32120 B1 MA 32120B1 MA 32465 A MA32465 A MA 32465A MA 32465 A MA32465 A MA 32465A MA 32120 B1 MA32120 B1 MA 32120B1
Authority
MA
Morocco
Prior art keywords
chemical compounds
new chemical
compounds
medicament
excessive
Prior art date
Application number
MA32465A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Ettmayer
Ioannis Sapountzis
Christian Klein
Andreas Mantoulidis
Steffen Steurer
Irene Waizenegger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38792475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32120(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32120B1 publication Critical patent/MA32120B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés chimiques de formule générale (1), dans laquelle les groupes r1 à r3, l sont défini tel que dans la revendication 1. Ces composés conviennent au traitement de maladies caractérisées par une prolifération excessive ou anormale de cellules et sont utilisés dans la préparation d'un médicament possédant les propriétés susmentionnées.
MA32465A 2007-07-02 2009-12-30 Nouveaux composes chimiques MA32120B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07111566 2007-07-02
PCT/EP2008/058433 WO2009003999A2 (fr) 2007-07-02 2008-07-01 Nouveaux composés chimiques

Publications (1)

Publication Number Publication Date
MA32120B1 true MA32120B1 (fr) 2011-03-01

Family

ID=38792475

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32465A MA32120B1 (fr) 2007-07-02 2009-12-30 Nouveaux composes chimiques

Country Status (21)

Country Link
US (1) US8889665B2 (fr)
EP (1) EP2173734B1 (fr)
JP (1) JP5511658B2 (fr)
KR (1) KR20100039849A (fr)
CN (1) CN101796045A (fr)
AR (1) AR067397A1 (fr)
AU (1) AU2008270300A1 (fr)
BR (1) BRPI0814601A2 (fr)
CA (1) CA2692383A1 (fr)
CL (1) CL2008001943A1 (fr)
CO (1) CO6251316A2 (fr)
EA (1) EA201000105A1 (fr)
EC (1) ECSP099823A (fr)
IL (1) IL202625A0 (fr)
MA (1) MA32120B1 (fr)
MX (1) MX2009013935A (fr)
PE (1) PE20090837A1 (fr)
TN (1) TN2009000551A1 (fr)
TW (1) TW200911789A (fr)
UY (1) UY31198A1 (fr)
WO (1) WO2009003999A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574621A (en) * 2006-07-07 2012-03-30 Boehringer Ingelheim Int Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumour agents
JP2010531850A (ja) * 2007-07-02 2010-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
MX2011003292A (es) 2008-09-29 2011-04-21 Boehringer Ingelheim Int Compuestos antiproliferativos.
CA2752265A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Derives pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
JP2010235575A (ja) * 2009-03-09 2010-10-21 Konica Minolta Holdings Inc 含窒素縮合複素環化合物の製造方法
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
EP2552905B1 (fr) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH Inhibiteurs de la kinase B-Raf
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103172617A (zh) * 2011-12-20 2013-06-26 天津市国际生物医药联合研究院 1,5-二取代-1,2,3-三氮唑三氟甲基类化合物的应用
CN103539784B (zh) * 2012-07-09 2016-08-17 中国科学院广州生物医药与健康研究院 杂环苯甲酰胺类化合物、药用组合物及其应用
WO2015143652A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143653A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143654A1 (fr) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2016161572A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et procédés associés
JP2018521021A (ja) 2015-06-11 2018-08-02 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ 排出ポンプ阻害剤及びその治療的使用
KR101723881B1 (ko) * 2016-03-28 2017-04-07 이화여자대학교 산학협력단 신규한 트리아졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 오로라 키나제 관련 약학적 조성물
EP3817811B1 (fr) * 2018-07-04 2024-04-03 Boehringer Ingelheim International GmbH Dérivés de triazole benzamide en tant qu'agonistes de gpr142
EP4146633A4 (fr) * 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. Composition destinée à être utilisée dans le traitement d'une maladie associée à apol1
WO2022188792A1 (fr) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 Composé hétérocyclique ayant une activité inhibitrice de protéine kinase, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
US20250275988A1 (en) * 2022-04-19 2025-09-04 Watershed Medical, Inc. Formulation for treating urinary system disorders
CN114805334B (zh) * 2022-05-24 2023-06-09 深圳大学 一种QC和GSK-3β多靶向抑制剂及其制备方法与应用
WO2024149728A1 (fr) * 2023-01-10 2024-07-18 Astrazeneca Ab (hétéro)anilines substituées et leur utilisation
CN116068110B (zh) * 2023-01-19 2024-11-22 武汉大学 叠氮质谱探针的合成方法及应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU507066B1 (en) 1977-09-06 1980-01-31 Sumitomo Chemical Company, Limited 2-Substituted-5-Hydroxy-1h-Imidazole 4-Carbozamide Derivatives
JPH03174153A (ja) 1989-09-20 1991-07-29 Fuji Photo Film Co Ltd カラー画像形成方法
PL184490B1 (pl) 1995-02-02 2002-11-29 Smithkline Beecham Plc Nowe pochodne indolu jako antagonista receptora T
WO1997003967A1 (fr) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Composes aromatiques substitues et leur utilisation pharmaceutique
WO2000047194A2 (fr) 1999-02-09 2000-08-17 3-Dimensional Pharmaceuticals, Inc. METHODES DE TRAITEMENT DE MALADIES ET PATHOLOGIES INDUITES PAR C1s, COMPOSES ET COMPOSITIONS PREPARES A CET EFFET
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2002069070A (ja) * 2000-04-07 2002-03-08 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
CA2437248A1 (fr) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
ES2338539T3 (es) 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
EP1567507B1 (fr) 2002-11-27 2006-06-14 Boehringer Ingelheim Pharmaceuticals Inc. Inhibiteurs de cytokines a base de derives de 1, 2, 3- triazole-amides
BRPI0414313A (pt) 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
WO2005030705A1 (fr) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
WO2005040152A1 (fr) 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Azolecarboxamides substitues par heterocyclylphenyle et heterocyclylpyridile
ES2360292T3 (es) 2003-12-03 2011-06-02 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de 1,2,3-triazol amida como inhibidores de la producción de citoquinas.
ATE432273T1 (de) 2004-03-09 2009-06-15 Boehringer Ingelheim Pharma 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n- arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
US7485657B2 (en) * 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
ES2465469T3 (es) * 2005-01-14 2014-06-05 Gilead Connecticut, Inc. Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
JP2007076376A (ja) 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
WO2007056016A2 (fr) 2005-11-02 2007-05-18 Kemia, Inc. Inhibiteurs de cytokine bisamide
WO2007075896A2 (fr) 2005-12-22 2007-07-05 Kemia, Inc. Inhibiteurs de cytokine heterocycliques
US20070155746A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
CA2647266A1 (fr) 2006-04-18 2007-10-25 Boehringer Ingelheim International Gmbh Procede de preparation de composes inhibiteurs des cytokines contenant des cycles 4- et 5-imidazolyle et leurs intermediaires
PE20080068A1 (es) 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
NZ574621A (en) 2006-07-07 2012-03-30 Boehringer Ingelheim Int Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumour agents
PE20080553A1 (es) 2006-07-07 2008-05-16 Schering Corp Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
EP2041138B1 (fr) 2006-07-07 2014-06-25 Bristol-Myers Squibb Company Inhibiteurs de pyrrolotriazine kinase
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
WO2008089034A2 (fr) 2007-01-11 2008-07-24 Kemia, Inc. Inhibiteurs de cytokine
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
JP2010531850A (ja) 2007-07-02 2010-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
MX2011003292A (es) 2008-09-29 2011-04-21 Boehringer Ingelheim Int Compuestos antiproliferativos.
CA2752265A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Derives pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (fr) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH Inhibiteurs de la kinase B-Raf
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
EP2173734A2 (fr) 2010-04-14
ECSP099823A (es) 2010-01-29
EP2173734B1 (fr) 2016-03-23
WO2009003999A3 (fr) 2009-07-16
US20110183952A1 (en) 2011-07-28
IL202625A0 (en) 2010-06-30
WO2009003999A2 (fr) 2009-01-08
CO6251316A2 (es) 2011-02-21
TN2009000551A1 (fr) 2011-03-31
JP2010531851A (ja) 2010-09-30
US8889665B2 (en) 2014-11-18
CL2008001943A1 (es) 2009-09-11
AR067397A1 (es) 2009-10-07
BRPI0814601A2 (pt) 2019-09-24
MX2009013935A (es) 2010-01-28
CN101796045A (zh) 2010-08-04
EA201000105A1 (ru) 2010-06-30
CA2692383A1 (fr) 2009-01-08
KR20100039849A (ko) 2010-04-16
PE20090837A1 (es) 2009-07-24
UY31198A1 (es) 2009-01-30
TW200911789A (en) 2009-03-16
AU2008270300A1 (en) 2009-01-08
JP5511658B2 (ja) 2014-06-04

Similar Documents

Publication Publication Date Title
MA32120B1 (fr) Nouveaux composes chimiques
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA30514B1 (fr) Nouveaux composes.
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
TN2013000349A1 (fr) Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA27697A1 (fr) Derive de phenethanolamine utilise dans le traitement des maladies respiratoires
TN2009000138A1 (fr) Biaryl-ether-urees
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
TN2009000450A1 (fr) Derives de pyridine
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA32656B1 (fr) Nouveaux composes chimiques
MY140187A (en) Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MA30289B1 (fr) Dérivés d'amines
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA34308B1 (fr) Triazolopyridines substituées
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer